Addition of rituximab to hyper-CVAD improves overall survival in newly diagnosed Burkitt leukemia/lymphoma from the Middle East and North Africa region

Simple item page
dc.contributor.authorNajla, S. Bin Sabbaren_US
dc.contributor.authorFatimah, S. Alowirdien_US
dc.contributor.authorFatimah, A. Basakranen_US
dc.contributor.authorLujain, A. Al-Badren_US
dc.contributor.authorRawan, A. Assirien_US
dc.contributor.authorWafa, A. Alshahranien_US
dc.contributor.authorAlaa, Althubaitien_US
dc.contributor.authorMoussab, Damlajen_US
dc.date.accessioned2020-05-06T08:50:40Z
dc.date.available2020-05-06T08:50:40Z
dc.date.issued2019-10
dc.description.abstractBackground: Burkitt leukemia/lymphoma (BL) is a highly aggressive malignancy treated with intensive combinational chemotherapy. However, there is paucity in the literature with regards to outcome in patients with BL from the Middle East and North Africa Region (MENA).Methods: We examined the impact of incorporation of the monoclonal antibody rituximab within a chemotherapy backbone of hyper-fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, cytarabine and methotrexate (hyper-CVAD). Between 2007 to 2016, a total of 21 patients were identified and data retrospectively collected with median follow up was 32 months (1.1-120). The cohort was stratified based on exposure to rituximab and there was no significant difference regarding gender, age, stage, presence of constitutional symptoms, baseline presenting blood counts and proportion of patients completing prescribed therapy regimen between the strata.Results: Estimated overall survival (OS) of the entire cohort at 2 years was 71.1%; however, patients who received rituximab in conjunction with hyper-CVAD had a statistically significant improvement in 2-year OS at 81.2% vs 40% (p=0.048).Conclusions: In conclusion, we observed that incorporation of rituximab within a hyper-CVAD backbone improved OS in BL patients from the MENA region. These results warrant further evaluation.en_US
dc.identifier.affiliationsDepartment of College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, KSAen_US
dc.identifier.affiliationsDepartment of College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, KSAen_US
dc.identifier.affiliationsDepartment of College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, KSAen_US
dc.identifier.affiliationsDepartment of College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, KSAen_US
dc.identifier.affiliationsDepartment of College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, KSAen_US
dc.identifier.affiliationsDepartment of College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, KSAen_US
dc.identifier.affiliationsDepartment of College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, KSADepartment of Oncology, King Abdulaziz Medical City, Riyadh, KSAen_US
dc.identifier.citationNajla S. Bin Sabbar, Fatimah S. Alowirdi, Fatimah A. Basakran, Lujain A. Al-Badr, Rawan A. Assiri, Wafa A. Alshahrani, Alaa Althubaiti, Moussab Damlaj. Addition of rituximab to hyper-CVAD improves overall survival in newly diagnosed Burkitt leukemia/lymphoma from the Middle East and North Africa region. International Journal of Community Medicine and Public Health. 2019 Oct; 6(10): 4199-4203en_US
dc.identifier.issn2394-6032
dc.identifier.issn2394-6040
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/201768
dc.languageenen_US
dc.publisherMedip Academyen_US
dc.relation.issuenumber10en_US
dc.relation.volume6en_US
dc.source.urihttps://dx.doi.org/10.18203/2394-6040.ijcmph20194475en_US
dc.subjectBurkitt lymphomaen_US
dc.subjectHyper-CVADen_US
dc.subjectRituximaben_US
dc.titleAddition of rituximab to hyper-CVAD improves overall survival in newly diagnosed Burkitt leukemia/lymphoma from the Middle East and North Africa regionen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijcmph2019v6n10p4199.pdf
Size:
251.45 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Community Medicine and Public Health